MediWound Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by MediWound Ltd., a foreign private issuer, for the month of October 2017. The filing primarily serves to disclose recent changes to the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
- Board Appointment (Chairman): On October 25, 2017, the Company appointed Mr. Stephen T. Wills as Chairman of its Board of Directors.
- Board Appointment (Director): On October 24, 2017, Mr. Assaf Segal was appointed to the Board of Directors, effective immediately, to serve until the 2018 annual meeting of shareholders.
Management Commentary and Background
Mr. Assaf Segal brings significant financial and biotechnology experience to the Board. He is currently the Chief Financial Officer at Clal Biotechnology Industries. Prior to this role, he was a Partner at Variance Economic Consulting for 11 years and held positions in corporate finance at Kesselman Corporate Finance-PricewaterhouseCoopers and as Head of the Economic Department at Amdocs. He holds an MBA in Finance & Information Systems and a B.A. in Economics and Statistics from The Hebrew University in Jerusalem.
Key Facts for Investor Verification
- Verify the official press release dated October 25, 2017, regarding the appointment of Mr. Stephen T. Wills as Chairman.
- Confirm the tenure and specific responsibilities of the newly appointed Director, Mr. Assaf Segal.
- Note that this filing contains no financial data; investors should refer to the most recent Form 20-F or quarterly reports for financial performance.